866-997-4948(US-Canada Toll Free)

Drug Overdose - Pipeline Review, H2 2018

Published By :

Global Markets Direct

Published Date : Sep 2018

Category :

Pharmaceutical

No. of Pages : 65 Pages

Drug Overdose - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose - Pipeline Review, H2 2018, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.

Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 1, 2, 1, 3, 2 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Drug Overdose - Overview
Drug Overdose - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Drug Overdose - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Overdose - Companies Involved in Therapeutics Development
Adamis Pharmaceuticals Corp
Adapt Pharma Ltd
Crossject SA
Fabentech SA
Icure Pharmaceutical Inc
Insys Therapeutics Inc
Klaria Pharma Holding AB
Opiant Pharmaceuticals Inc
Orexo AB
PledPharma AB
Drug Overdose - Drug Profiles
Antibody for Drug Overdose, Opioid Addiction and Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalmefene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPNT-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
physostigmine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Alzheimer's Disease and Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug Overdose - Dormant Projects
Drug Overdose - Discontinued Products
Drug Overdose - Product Development Milestones
Featured News & Press Releases
Jul 12, 2018: Aetna Donates Narcan to Wayne County
Jun 26, 2018: Albertsons Companies Offers Increased Access to Naloxone
Jun 25, 2018: Opiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
May 29, 2018: ADAPT Pharma Launches New Online Platform for NARCAN
May 09, 2018: Quebec Government makes NARCAN Nasal Spray free to anyone 14 years or older through Free naloxone program
Apr 30, 2018: A Retrospective Analysis & Literature Review Published in Pain Management on the Pharmacokinetic Properties of Naloxone Approved for Community Use Highlights Bioequivalence of Dose & Usability
Apr 26, 2018: Adapt Pharma donates 20,000 doses of NARCAN (naloxone HCl) Nasal Spray to the National Council for Behavioral Health and its Residential Treatment Member Organizations
Apr 25, 2018: A Retrospective Literature Review Published in Pain Management on Prescribing Naloxone for Opioid Overdose Intervention Highlights Opportunities to Expand Community Access to Help Reduce Fatalities
Apr 18, 2018: Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Apr 09, 2018: Adapt Pharma Welcomes Canadian & Ontario Governments Programs Providing NARCAN (naloxone HCl) Nasal Spray Free of Charge to NIHB Clients and All Ontarians through Pharmacies
Apr 05, 2018: ADAPT Pharma Welcomes Surgeon General Naloxone Advisory
Apr 05, 2018: CVS Health Expands Efforts to Educate Patients about Naloxone
Apr 04, 2018: Cardinal Health Begins Donation of Over 80,000 Doses of Life-Saving Narcan for Distribution to Law Enforcement and First Responders in Appalachia
Mar 19, 2018: ADAPT Pharma Expands Program Offering Free NARCAN (naloxone HCl) Nasal Spray to Eligible Schools and Universities
Mar 05, 2018: Adapt Pharma Expands Technical and R&D Teams
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Drug Overdose, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Drug Overdose - Pipeline by Adamis Pharmaceuticals Corp, H2 2018
Drug Overdose - Pipeline by Adapt Pharma Ltd, H2 2018
Drug Overdose - Pipeline by Crossject SA, H2 2018
Drug Overdose - Pipeline by Fabentech SA, H2 2018
Drug Overdose - Pipeline by Icure Pharmaceutical Inc, H2 2018
Drug Overdose - Pipeline by Insys Therapeutics Inc, H2 2018
Drug Overdose - Pipeline by Klaria Pharma Holding AB, H2 2018
Drug Overdose - Pipeline by Opiant Pharmaceuticals Inc, H2 2018
Drug Overdose - Pipeline by Orexo AB, H2 2018
Drug Overdose - Pipeline by PledPharma AB, H2 2018
Drug Overdose - Dormant Projects, H2 2018
Drug Overdose - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Drug Overdose, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *